Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

AP Kater, S Kersting, Yvette van Norden, J Dubois, JA Dobber, CH Mellink, LM Evers, F Boer, J Schreurs, E van der Spek, H Visser, C Idink, S Wittebol, M Hoogendoorn, SH Tonino, M Mobasher, M-D Levin

Research output: Contribution to journalArticleAcademicpeer-review

22 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)3566-3571
Number of pages6
JournalBlood advances
Issue number24
Publication statusPublished - 2018

Research programs

  • EMC OR-01

Cite this